Add Lenacapavir to Your List of PrEP Recommendations
September 2025
Lenacapavir (Yeztugo) is the first TWICE-YEARLY subcutaneous injectable option for HIV pre-exposure prophylaxis (PrEP).
Lenacapavir is a long-acting HIV capsid inhibitor. It joins the oral, daily PrEP options emtricitabine/tenofovir DISOPROXIL fumarate (Truvada) and emtricitabine/tenofovir ALAFENAMIDE (Descovy)...and the every-two-month IM injectable option, cabotegravir (Apretude).
In studies comparing injectable lenacapavir with emtricitabine/ tenofovir DISOPROXIL fumarate, either option is shown to be over 99% effective in preventing HIV...when taken as prescribed.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote